ALLO / SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Christine Cassiano – Ch more_horizontal

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion more_horizontal

Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate more_horizontal

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief more_horizontal

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares t more_horizontal

Allogene Therapeutics, Inc. is the leading developer of allogeneic CAR-T. There was a time when its logic appealed to me. Lately, however, I have incr more_horizontal

SOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pion more_horizontal

The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 210.2% upside in the stock. While this highly sought-after metric has more_horizontal